Preview

Epilepsy and paroxysmal conditions

Advanced search

Acute symptomatic seizures during haematopoietic stem cell transplantation

https://doi.org/10.17749/2077-8333/epi.par.con.2021.049

Full Text:

Abstract

Acute symptomatic epileptic seizures are one of the complications of hematopoietic stem cell transplantation. The etiological factors leading to the development of this complication differ from those in the general population, while the significance of each of them is different depending on the time after transplantation. We analyze the literature data on the role of drugs, metabolic disorders and infectious complications, as well as the structural pathology of the brain substance in the development of acute symptomatic seizures in patients with oncohematological pathology. We also consider the clinical features of symptomatic epileptic seizures and the possible prognostic significance of their development in patients who underwent hematopoietic stem cell transplantation.

About the Authors

Ya. B. Skiba
Pavlov First Saint Petersburg State Medical University
Russian Federation

Yaroslav B. Skiba, MD, PhD, Neurologist, Gorbacheva Research Institute of Pediatric Oncology, Hematology and Trasplantology

Scopus Author ID: 57211950985

WoS ResearcherID: ABC-9723-2020

RSCI SPIN-code: 1273-0742

6-8 Lev Tolstoi Str., Saint Petersburg 197022



A. Yu. Polushin
Pavlov First Saint Petersburg State Medical University
Russian Federation

Aleksey Yu. Polushin, MD, PhD, Assistant Professor, Chair of Neurology, Neurologist, Gorbacheva Research Institute of Pediatric
Oncology, Hematology and Trasplantology

Scopus Author ID: 57195962540

RSCI SPIN-code: 8123-7779

6-8 Lev Tolstoi Str., Saint Petersburg 197022



M. Yu. Prokudin
Pavlov First Saint Petersburg State Medical University
Russian Federation

Mikhail Yu. Prokudin, MD, PhD, Astvatsaturov Chair of Nervous Diseases

RSCI SPIN-code: 4021-4432

6-8 Lev Tolstoi Str., Saint Petersburg 197022



M. D. Vladovskaya
Pavlov First Saint Petersburg State Medical University
Russian Federation

Mariya D. Vladovskaya, MD, PhD, Head of the Department of Hospital Registers, Gorbacheva Research Institute of Pediatric
Oncology, Hematology and Trasplantology

Scopus Author ID: 57194451100

RSCI SPIN-code: 9257-2440

6-8 Lev Tolstoi Str., Saint Petersburg 197022



A. D. Kulagin
Pavlov First Saint Petersburg State Medical University
Russian Federation

Aleksandr D. Kulagin, Dr. Med. Sc., Acting Director, Gorbacheva Research Institute of Pediatric Oncology, Hematology and
Trasplantology

Scopus Author ID: 7003340367

WoS ResearcherID: L-9795-2014

RSCI SPIN-code: 2667-4966

6-8 Lev Tolstoi Str., Saint Petersburg 197022



References

1. Афанасьев Б.В., Зубаровская Л.С., Моисеев И.С. Аллогенная трансплантация гемопоэтических стволовых клеток у детей: настоящее, проблемы, перспективы. Российский журнал детской гематологии и онкологии. 2015; 2 (2): 28–42. https://doi.org/10.17650/2311-1267-2015-2-2-28-42.

2. Afanasyeva K.S., Barabanshchikova M.V., Bondarenko S.N., et al. Indications for hematopoietic stem cell transplantation. Cellular Therapy and Transplantation. 2019; 8 (4): 101–45. https://doi.org/10.18620/ctt-1866-8836-2019-8-4-101-145.

3. Паровичникова Е.Н., Савченко В.Г. Российские многоцентровые исследования по лечению острых лейкозов. Терапевтический архив. 2019; 91 (7): 4–13. https://doi.org/10.26442/00403660.2019.07.000325.

4. Bondarenko S.N., Moiseev I.S., Slesarchuk O.A., et al. Allogeneic hematopoietic stem cell transplantation in children and adults with acute lymphoblastic leukemia. Cellular Therapy and Transplantation. 2016; 5 (2): 12–20. https://doi.org/10.18620/1866-8836-2016-5-2-12-20.

5. Паина О.В., Рахманова Ж.З., Кожокарь П.В. и др. Результаты аллогенной трансплантации гемопоэтических стволовых клеток от совместимого неродственного и родственного гаплоидентичного донора у детей с младенческим лейкозом высокой группы риска в первой и второй ремиссии. Вопросы гематологии/ онкологии и иммунопатологии в педиатрии. 2020; 19 (2): 30–7. https://doi.org/10.24287/1726-1708-2020-19-2-30-37.

6. Kang J.M., Kim Y.J., Kim J.Y., et al. Neurologic complications after allogeneic hematopoietic stem cell transplantation in children: analysis of prognostic factors. Biol Blood Marrow Transplant. 2015; 21 (6): 1091–8. https://doi.org/10.1016/j.bbmt.2015.02.007.

7. Zhang X.H., Xu L.P., Liu D.H., et al. Epileptic seizures in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors, and survival rates. Clin Transplant. 2013; 27 (1): 80–9. https://doi.org/10.1111/ctr.12000.

8. Полушин А.Ю., Владовская М.Д., Моисеев И.С. и др. Проблема неврологических осложнений после неродственной трансплантации гемопоэтических стволовых клеток и таргетной терапии при злокачественных гематологических заболеваниях. Сборник материалов научной конференции XXI «Давиденковские чтения». СПб.: Человек и его здоровье; 2019: 256–8.

9. Cordelli D.M., Masetti R., Zama D., et al. Etiology, characteristics and outcome of seizures after pediatric hematopoietic stem cell transplantation. Seizure. 2014; 23 (2): 140–5. https://doi.org/10.1016/j.seizure.2013.11.003.

10. Lipatova L.V., Rudakova I.G., Sivakova N.A., Kapustina T.V. Acute symptomatic epileptic seizures and status epilepticus. Zh Nevrol Psikhiatr Im S S Korsakova. 2015; 115 (4): 24–9 (in Russ.) https://doi.org/10.17116/jnevro20151154124-29.

11. Annegers J.F., Hauser W.A., Lee J.R, Rocca W.A. Incidence of acute symptomatic seizures in Rochester, Minnesota, 1935–1984. Epilepsia. 1995; 36 (4): 327–33. https://doi.org/10.1111/j.1528-1157.1995.tb01005.x.

12. Costello D.J., Cole A.J. Treatment of acute seizures and status epilepticus. J Intensive Care Med. 2007; 22 (6): 319–47. https://doi.org/10.1177/0885066607307506.

13. Khan R.B., Morris E.B., Pui C.H., et al. Long-term outcome and risk factors for uncontrolled seizures after a first seizure in children with hematological malignancies. J Child Neurol. 2014; 29 (6): 774–81. https://doi.org/10.1177/0883073813488675.

14. Caselli D., Ziino O., Bartoli A., et al. Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan. Bone Marrow Transplant. 2008; 42 (2): 135–6. https://doi.org/10.1038/bmt.2008.91.

15. Tsujimoto S.I., Shirai R., Utano T., et al. Comparison of clonazepam and levetiracetam in children for prevention of busulfan-induced seizure in hematopoietic stem cell transplantation. Int J Hematol. 2020; 111 (3): 463–6. https://doi.org/10.1007/s12185-019-02795-8.

16. Della Puppa A., Denaro L., Rossetto M., et al. Postoperative seizure in high grade glioma patients treated with BCNU wafers. A monoinstitutional experience. J Neurooncol. 2011; 105 (2): 275–80. https://doi.org/10.1007/s11060-011-0577-6.

17. Biran N., Rowley S.D., Vesole D.H., et al. A phase i/ii study of escalating doses of bortezomib in conjunction with high-dose melphalan as a conditioning regimen for salvage autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2016; 22 (12): 2165–71. https://doi.org/10.1016/j.bbmt.2016.08.017.

18. Ryan S.A., Maceneaney P., O'Reilly S.P., et al. Reversible posterior leukoencephalopathy induced by carboplatin and etoposide. Med Oncol. 2012; 29 (2): 1287–91. https://doi.org/10.1007/s12032-011-9898-8.

19. Kushner B.H., Cheung N.K., Kramer K., et al. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone Marrow Transplant. 2001; 28 (6): 551–6. https://doi.org/10.1038/sj.bmt.1703213.

20. Beitinjaneh A., McKinney A.M., Cao Q., Weisdorf D.J. Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011; 17 (3): 300–8. https://doi.org/10.1016/j.bbmt.2010.04.003.

21. Meldgaard Knudsen L., Jensen L., Gaarsdal E., et al. A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. Bone Marrow Transplant. 2000; 26 (7): 717–22. https://doi.org/10.1038/sj.bmt.1702609.

22. Hwang S.B., Lee H.Y., Kim H.Y., et al. Life-threatening acute hyponatremia with generalized seizure induced by low-dose cyclophosphamide in a patient with breast cancer. J Breast Cancer. 2011; 14 (4): 345–8. https://doi.org/10.4048/jbc.2011.14.4.345.

23. Kawakami K., Ito R., Kageyama Y., et al. Superior sagittal sinus thrombosis after intrathecal chemotherapy and intravenous high-dose cytarabine in an acute myeloid leukemia case with t(8;21)(q22;q22). Rinsho Ketsueki. 2016; 57 (4): 477–82 (in Japanese). https://doi.org/10.11406/rinketsu.57.477.

24. Bauwens D., Hantson P., Laterre P.F., et al. Recurrent seizure and sustained encephalopathy associated with dimethylsulfoxidepreserved stem cell infusion. Leukemia&Lymphoma. 2005; 46 (11): 1671–4. https://doi.org/10.1080/10428190500235611.

25. Maral S., Albayrak M., Pala C., et al. Dimethyl sulfoxide-induced tonic-clonic seizure and cardiac arrest during infusion of autologous peripheral blood stem cells. Cell Tissue Bank. 2018; 19 (4): 831–2. https://doi.org/10.1007/s10561-018-9718-x.

26. Hequet O., Dumontet C., El Jaafari-Corbin A., et al. Epileptic seizures after autologous peripheral blood progenitor infusion in a patient treated with high-dose chemotherapy for myeloma. Bone Marrow Transplant. 2002; 29 (6): 544. https://doi.org/10.1038/sj.bmt.1703383.

27. Inaba H., Khan R.B., Laningham F.H., et al. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol. 2008; 19 (1): 178–84. https://doi.org/10.1093/annonc/mdm466.

28. Rao R.D., Swanson J.W., Dejesus R.S., et al. Methotrexate induced seizures associated with acute reversible magnetic resonance imaging (MRI) changes in a patient with acute lymphoblastic leukemia. Leuk Lymphoma. 2002; 43 (6): 1333–6. https://doi.org/10.1080/10428190290026402.

29. Abraham P., Longardner K., Chen P., et al. Case 279: central-variant posterior reversible encephalopathy syndrome. Radiology. 2020; 296 (1): 239–43. https://doi.org/10.1148/radiol.2020181547.

30. Teimouri A., Ahmadi S.R., Anavri Ardakani S., Foroughian M. Cyclosporine-A-based immunosuppressive therapy-induced neurotoxicity: a case report. Open Access Emerg Med. 2020; 2000 (12): 93–7. https://doi.org/10.2147/OAEM.S241501.

31. He W., Chen J., Wang Y.Y., et. al. Sirolimus improves seizure control in pediatric patients with tuberous sclerosis: a prospective cohort study. Seizure. 2020; 79: 20–6. https://doi.org/10.1016/j.seizure.2020.03.018.

32. Xie M., Rao W., Sun L.Y., et al. Tacrolimus-related seizure after pediatric liver transplantation – a single-center experience. Pediatr Transplant. 2014; 18 (1): 58–63. https://doi.org/10.1111/petr.12198.

33. Sevmis S., Karakayali H., Emiroglu R., et al. Tacrolimus-related seizure in the early postoperative period after liver transplantation. Transplant Proc. 2007; 39 (4): 1211–3. https://doi.org/10.1016/j.transproceed.2007.02.049.

34. Vesole A.S., Nagahama Y., Granner M.A., et al. Drug-resistant epilepsy development following stem cell transplant and cyclosporine neurotoxicity induced seizures: case report in an adult and analysis of reported cases in the literature. Epilepsy Behav Case Rep. 2018; 10: 8–13. https://doi.org/10.1016/j.ebcr.2018.01.002.

35. Kadish N.E., Riedel C., Stephani U., Wiegand G. Developmental outcomes in children/adolescents and one adult with tuberous sclerosis complex (TSC) and refractory epilepsy treated with everolimus. Epilepsy Behav. 2020; 111: 107182. https://doi.org/10.1016/j.yebeh.2020.107182.

36. Hung J.J., Huang J.L. Etanercept therapy in children with juvenile rheumatoid arthritis. J Microbiol Immunol Infect. 2005; 38 (6): 444–6.

37. Cannon J.P., Lee T.A., Clark N.M., et al. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother. 2014; 69 (8): 2043–55. https://doi.org/10.1093/jac/dku111.

38. Conley T.E., Mohiuddin A., Naz N. Severe co-trimoxazole-induced hypoglycaemia in a patient with microscopic polyangiitis. BMJ Case Rep. 2017; 2017: bcr2016218976. https://doi.org/10.1136/bcr-2016-218976.

39. Balkan I.I., Delil S., Karabacak E.R., et al. Linezolid-induced complex partial seizure in a patient without epilepsy. Int J Infect Dis. 2015; 35: 120. https://doi.org/10.1016/j.ijid.2015.05.007.

40. Lin C.S., Cheng C.J., Chou C.H., Lin S.H. Piperacillin/tazobactaminduced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis. Am J Med Sci. 2007; 333 (3): 181–4. https://doi.org/10.1097/MAJ.0b013e31803195e7.

41. Chow K.M., Szeto C.C., Hui A.C., et al. Retrospective review of neurotoxicity induced by cefepime and ceftazidime. Pharmacotherapy. 2003; 23 (3): 369–73. https://doi.org/10.1592/phco.23.3.369.32100.

42. Grill M.F., Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother. 2008; 42 (12): 1843–50. https://doi.org/10.1345/aph.1L307.

43. Agbaht K., Bitik B., Piskinpasa S., et al. Ciprofloxacin-associated seizures in a patient with underlying thyrotoxicosis: case report and literature review. Int J Clinl Pharmacol Ther. 2009; 47 (5): 303–10. https://doi.org/10.5414/cpp47303.

44. Barton T.L., Roush M.K., Dever L.L. Seizures associated with ganciclovir therapy. Pharmacotherapy. 1992; 12 (5): 413–5.

45. Foroughinia F., Baniasadi S., Seifi S., Fahimi F. Vincristine-induced seizure potentiated by itraconazole following RCHOP chemotherapy for diffuse large B-cell lymphoma. Curr Drug Saf. 2012; 7 (5): 372–4. https://doi.org/10.2174/157488612805076633.

46. Hamdy D.A., El-Geed H., El-Salem S., Zaidan M. Posaconazolevincristine coadministration triggers seizure in a young female adult: a case report. Case Rep Hematol. 2012; 2012: 343742. https://doi.org/10.1155/2012/343742.

47. Beghi E., Carpio A., Forsgren L., et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010; 51 (4): 671–5. https://doi.org/10.1111/j.1528-1167.2009.02285.x.

48. Common Terminology Criteria for Adverse Events (CTCAE). URL: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (дата обращения 02.04.2021).

49. Saner F., Gu Y., Minouchehr S., et al. Neurological complications after cadaveric and living donor liver transplantation. J Neurol. 2006; 253 (5): 612–7. https://doi.org/10.1007/s00415-006-0069-3.

50. Forgacs B., Merhav H.J., Lappin J., Mieles L. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. Transplant Proc. 2005; 37 (4): 1912–4. https://doi.org/10.1016/j.transproceed.2005.02.101.

51. Shuto H., Kataoka Y., Fujisaki K., et al. Inhibition of GABA system involved in cyclosporine-induced convulsions. Life Sci. 1999; 65 (9): 879–87. https://doi.org/10.1016/s0024-3205(99)00318-5.

52. Klawitter J., Gottschalk S., Hainz C., et al. Immunosuppressant neurotoxicity in rat brain models: oxidative stress and cellular metabolism. Chem Res Toxicol. 2010; 23 (3): 608–19. https://doi.org/10.1021/tx900351q.

53. Katsarou A.M., Moshé S.L., Galanopoulou A.S. Interneuronopathies and their role in early life epilepsies and neurodevelopmental disorders. Epilepsia Open. 2017; 2 (3): 284–306. https://doi.org/10.1021/tx900351q10.1002/epi4.12062.

54. Wong M., Yamada K.A. Cyclosporine induces epileptiform activity in an in vitro seizure model. Epilepsia. 2000; 41 (3): 271–6. https://doi.org/10.1111/j.1528-1157.2000.tb00155.x.

55. Li Y., Wang H., Han D., et al. Acute symptomatic seizure due to tacrolimus-related encephalopathy after liver transplantation: two case reports. J Int Med Res. 2019; 47 (12): 6397–403. https://doi.org/10.1177/0300060519883750.

56. Savolainen H., Tenhunen R. Inhibition of heme synthase in brain and liver by low-level peroral sulfite exposure. Res Commun Chem Pathol Pharmacol. 1982; 36 (3): 511–4.

57. Chen-Plotkin A.S., Vossel K.A., Samuels M.A., Chen M.H. Encephalopathy, stroke, and myocardial infarction with DMSO use in stem cell transplantation. Neurology. 2007; 68 (11): 859–61. https://doi.org/10.1212/01.wnl.0000256716.04218.5b.

58. Ruiz-Delgado G.J., Mancías-Guerra C., Tamez-Gómez E.L., et al. Dimethyl sulfoxide-induced toxicity in cord blood stem cell transplantation: report of three cases and review of the literature. Acta Haematol. 2009; 122 (1): 1–5. https://doi.org/10.1159/000227267.

59. Pillinger K.E., Bouchard J., Withers S.T., et al. Inpatient Antibiotic Stewardship Interventions in the adult oncology and hematopoietic stem cell transplant population: a review of the literature. Ann Pharmacother. 2020; 54 (6): 594–10. https://doi.org/10.1177/1060028019890886.

60. Rival M., Chetioui A., Tailland M., Renard D. Linezolid-induced status epilepticus. Acta Neurol Belg. 2020; 120 (5): 1231–2. https://doi.org/10.1007/s13760-020-01333-2.

61. Bora I., Demir A.B., Uzun P. Nonconvulsive status epilepticus cases arising in connection with cephalosporins. Epilepsy Behav Case Rep. 2016; 6: 23–7. https://doi.org/10.1016/j.ebcr.2016.04.005.

62. Meyer M.A. Myoclonic jerks secondary to piperacillin and nafcillin. Neurol Int. 2014; 6 (2): 5349. https://doi.org/10.4081/ni.2014.5349.

63. Jang J.H., Song K.S., Bang J.S., et al. What should be considered to cause the early post-craniotomy seizure: antibiotics (cefazolin) irrigation. J Korean Neurosurg Soc. 2015; 58 (5): 462–6. https://doi.org/10.3340/jkns.2015.58.5.462.

64. McCune J.S., Wang T., Bo-Subait K., et al. Association of antiepileptic medications with outcomes after allogeneic hematopoietic cell transplantation with busulfan/cyclophosphamide conditioning. Biol Blood Marrow Transplant. 2019; 25 (7): 1424–31. https://doi.org/10.1016/j.bbmt.2019.03.001.

65. Nardone R., Brigo F., Trinka E. Acute symptomatic seizures caused by electrolyte disturbances. J Clin Neurol. 2016; 12 (1): 21–33. https://doi.org/10.3988/jcn.2016.12.1.21.

66. Schwartzkroin P.A., Baraban S.C., Hochman D.W. Osmolarity, ionic flux, and changes in brain excitability. Epilepsy Res. 1998; 32 (1-2): 275–85. https://doi.org/10.1016/s0920-1211(98)00058-8.

67. Filippatos T.D., Milionis H.J., Elisaf M.S. Alterations in electrolyte equilibrium in patients with acute leukemia. Eur J Haematol. 2005; 75 (6): 449–60. https://doi.org/10.1111/j.1600-0609.2005.00547.x.

68. Anandan A., Kolk M., Ferrari N., et al. Serum electrolyte dynamics in multiple myeloma patients undergoing autologous haematopoietic stem cell transplantation. Nephrology (Carlton). 2020; 25 (6): 450–6. https://doi.org/10.1111/nep.13712.

69. Milionis H.J., Bourantas C.L., Siamopoulos K.C., et al. Acid-base and electrolyte abnormalities in patients with acute leukemia. Am J Hematol. 1999; 62 (4): 201–7. https://doi.org/10.1002/(sici)1096-8652(199912)62:4<201::aid-ajh1>3.0.co;2-1.

70. Philibert D., Desmeules S., Filion A., et al. Incidence and severity of early electrolyte abnormalities following autologous haematopoietic stem cell transplantation. Nephrol Dial Transplant. 2008; 23 (1): 359–63. https://doi.org/10.1093/ndt/gfm571.

71. Van Amelsvoort T., Bakshi R., Devaux C.B., Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia. 1994; 35 (1): 181–8. https://doi.org/10.1111/j.1528-1157.1994.tb02930.x.

72. de Leeuw D.C., Kooter A.J. Transient seizure-induced sodium increase camouflaging a symptomatic hyponatremia. BMJ Case Rep. 2020; 13 (1): e229328. https://doi.org/10.1136/bcr-2019-229328.

73. Pilato F., Distefano M., Calandrelli R. Posterior reversible encephalopathy syndrome and reversible cerebral vasoconstriction syndrome: clinical and radiological considerations. Front Neurol. 2020; 11: 34. https://doi.org/10.3389/fneur.2020.00034.

74. Chen Q., Zhao X., Fu H.X., et al. Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplant. 2020; 55 (10): 2035–42. https://doi.org/10.1038/s41409-020-0894-5.

75. Datar S., Singh T., Rabinstein A.A., et al. Long-term risk of seizures and epilepsy in patients with posterior reversible encephalopathy syndrome. Epilepsia. 2015; 56 (4): 564–8. https://doi.org/10.1111/epi.12933.

76. Hammerstrom A.E., Howell J., Gulbis A., et al. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol. 2013; 88 (4): 301–5. https://doi.org/10.1002/ajh.23402.

77. Gaziev J., Marziali S., Paciaroni K., et al. Posterior reversible encephalopathy syndrome after hematopoietic cell transplantation in children with hemoglobinopathies. Biol Blood Marrow Transpl. 2017; 23 (9): 1531–40. https://doi.org/10.1016/j.bbmt.2017.05.033.

78. April D., Lall N., Steven A. Stroke-like migraine attacks after radiation therapy syndrome. Ochsner J. 2020; 20 (1): 6–9. https://doi.org/10.31486/toj.19.0090.

79. Kerklaan J.P., Lycklama á Nijeholt G.J., Wiggenraad R.G., et al. SMART syndrome: a late reversible complication after radiation therapy for brain tumours. J Neurol. 2011; 258 (6): 1098–104. https://doi.org/10.1007/s00415-010-5892-x.

80. Farid K., Meissner W.G., Samier-Foubert A., et al. Normal cerebrovascular reactivity in stroke-like migraine attacks after radiation therapy syndrome. Clin Nucl Med. 2010; 35 (8): 583–5. https://doi.org/10.1097/RLU.0b013e3181e4db6f.

81. Suarez Montero J.C., Caballero Gonzalez A.C., Martín Aguilar L., Mancebo Cortés J. Immune effector cell-associated neurotoxicity syndrome: a therapeutic approach in the critically ill. Med Intensiva. 2020: S0210-5691(20)30244-8. https://doi.org/10.1016/j.medin.2020.06.014.

82. Perrin P., Collongues N., Baloglu S., et al. Cytokine release syndromeassociated encephalopathy in patients with COVID-19. Eur J Neurol. 2021; 28 (1): 248–58. https://doi.org/10.1111/ene.14491.

83. Borrega J.G., Gödel P., Rüger M.A., et al. In the eye of the storm: immune-mediated toxicities associated with CAR-T cell therapy. Hemasphere. 2019; 3 (2): e191. https://doi.org/10.1097/HS9.0000000000000191.

84. Gust J., Finney O.C., Li D., et al. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy. Ann Neurol. 2019; 86 (1): 42–54. https://doi.org/10.1002/ana.25502.

85. Gust J., Hay K.A., Hanafi L.A., et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017; 7 (12): 1404–9. https://doi.org/10.1158/2159-8290.CD-17-0698.

86. Zheng W. Neurotoxicology of the brain barrier system: new implications. J Toxicol Clin Toxicol. 2001; 39 (7): 711–9. https://doi.org/10.1081/clt-100108512.

87. Martell R.W., Sher C., Jacobs P., Monteagudo F. High-dose busulfan and myoclonic epilepsy. Ann Intern Med. 1987; 106 (1): 173. https://doi.org/10.7326/0003-4819-106-1-173_1.

88. Janssen S., Bloem B.R., van de Warrenburg B.P. The clinical heterogeneity of drug-induced myoclonus: an illustrated review. J Neurol. 2017; 264 (8): 1559–66. https://doi.org/10.1007/s00415-016-8357-z.

89. Dowling M.R., Li S., Dey B.R., et al. Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact. Bone Marrow Transplant. 2018; 53 (2): 199–206. https://doi.org/10.1038/bmt.2017.239.

90. Hamidieh A.A., Hamedani R., Hadjibabaie M., et al. Oral lorazepam prevents seizure during high-dose busulfan in children undergoing hematopoietic stem cell transplantation: a prospective study. Pediatr Hematol Oncol. 2010; 27 (7): 529–33. https://doi.org/10.3109/08880018.2010.496895.

91. Ruiz-Argüelles G.J., Gomez-Almaguer D., Steensma D.P. Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting. Am J Hematol. 2012; 87 (9): 941. https://doi.org/10.1002/ajh.23270.

92. Diaz-Carrasco M.S., Olmos R., Blanquer M., et al. Clonazepam for seizure prophylaxis in adult patients treated with high dose busulfan. Int J Clin Pharm. 2013; 35 (3): 339–43. https://doi.org/10.1007/s11096-013-9768-x.

93. Chan K.W., Mullen C.A., Worth L.L., et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant. 2002; 29 (12): 963–5. https://doi.org/10.1038/sj.bmt.1703593.

94. Hassan M., Oberg G., Björkholm M., et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol. 1993; 33 (3): 181–6. https://doi.org/10.1007/BF00686213.

95. Carreras E., Cahn J.Y., Puozzo C., et al. Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. Anticancer Res. 2010; 30 (7): 2977–84.

96. Chaguaceda C., Aguilera-Jiménez V., Gutierrez G., et al. Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant. Int J Clin Pharm. 2020; 42 (2): 351–4. https://doi.org/10.1007/s11096-020-00977-7.

97. Floeter A.E., Mccune J.S. Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. J Oncol Pharm Pract. 2017; 23 (5). https://doi.org/10.1177/1078155216651128.

98. Eberly A.L., Anderson G.D., Bubalo J.S., McCune J.S. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy. 2008; 28 (12): 1502–10. https://doi.org/10.1592/phco.28.12.1502.

99. Marcus R.E., Goldman J.M. Convulsions due to high-dose busulphan. Lancet. 1984; 2 (8417-8418): 1463. https://doi.org/10.1016/s0140-6736(84)91649-0.

100. Vassal G., Deroussent A., Hartmann O., et al.. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990; 50 (19): 6203–7.

101. Woodward S. Management of faecal incontinence in graft-versus-host disease. Br J Nurs. 2012; 21 (2): 84–8. https://doi.org/10.12968/bjon.2012.21.2.84.


For citation:


Skiba Ya.B., Polushin A.Yu., Prokudin M.Yu., Vladovskaya M.D., Kulagin A.D. Acute symptomatic seizures during haematopoietic stem cell transplantation. Epilepsy and paroxysmal conditions. 2021;13(1):65-82. (In Russ.) https://doi.org/10.17749/2077-8333/epi.par.con.2021.049

Views: 82


ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)